Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc. | Executive Chairman of the Board and Global Chief Scientific & Medical Officer | 865.34k | -- | 1953 |
| Mr. Richard Gerald Adcock | President, CEO & Director | 1.16M | -- | 1969 |
| Mr. David C. Sachs | Chief Financial Officer | 824.62k | -- | 1978 |
| Dr. Barry J. Simon M.D. | Chief Corporate Affairs Officer & Director | -- | -- | 1965 |
| Dr. Leonard S. Sender M.D. | Chief Operating Officer | -- | -- | -- |
| Ms. Regan J. Lauer | Chief Accounting Officer | -- | -- | 1970 |
| Dr. Enrique Diloné Ph.D., RAC | Chief Technology Officer | -- | -- | 1967 |
| Mr. Jason R. Liljestrom J.D. | General Counsel & Corporate Secretary | -- | -- | 1983 |
| Ms. Sarah Singleton | Chief Communications Officer & Head of Patient Advocacy | -- | -- | -- |
| Dr. Sandeep K. Reddy M.D. | Chief Medical Officer | -- | -- | -- |
ImmunityBio, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 672
Description
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
Corporate Governance
Upcoming Events
March 17, 2025 at 8:00 PM UTC - March 21, 2025 at 8:00 PM UTC
ImmunityBio, Inc. Earnings Date